NVAX vs. AZN

Last updated Apr 2, 2026

Compare and contrast key facts about Novavax, Inc. (NVAX) and AstraZeneca PLC (AZN).

Performance

NVAX vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novavax, Inc. (NVAX) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

NVAX vs. AZN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NVAX Novavax, Inc.	19.35%	-16.42%	67.50%	-53.31%	-92.81%	28.30%	2,701.76%	-89.18%	48.39%	-1.59%
AZN AstraZeneca PLC	11.46%	43.30%	-0.62%	1.44%	19.14%	19.66%	3.12%	35.68%	13.86%	33.10%

Fundamentals

Market Cap NVAX : $1.39B AZN : $313.54B
EPS NVAX : $2.58 AZN : $6.55
PE Ratio NVAX : 3.11 AZN : 30.64
PS Ratio NVAX : 1.22 AZN : 5.33
Total Revenue (TTM) NVAX : $1.12B AZN : $58.74B
Gross Profit (TTM) NVAX : $1.05B AZN : $48.11B
EBITDA (TTM) NVAX : $452.80M AZN : $19.83B

Returns By Period

In the year-to-date period, NVAX achieves a 19.35% return, which is significantly higher than AZN's 11.46% return. Over the past 10 years, NVAX has underperformed AZN with an annualized return of -23.02%, while AZN has yielded a comparatively higher 16.92% annualized return.

NVAX

• 1D: -1.47%
• 1M: -20.67%
• YTD: 19.35%
• 6M: -15.58%
• 1Y: 33.67%
• 3Y*: 4.99%
• 5Y*: -46.66%
• 10Y*: -23.02%

AZN

• 1D: 1.78%
• 1M: -1.47%
• YTD: 11.46%
• 6M: 21.46%
• 1Y: 42.12%
• 3Y*: 15.74%
• 5Y*: 17.86%
• 10Y*: 16.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NVAX vs. AZN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVAX

NVAX Risk / Return Rank: 57
NVAX Sharpe Ratio Rank: 56
NVAX Sortino Ratio Rank: 61
NVAX Omega Ratio Rank: 57
NVAX Calmar Ratio Rank: 57
NVAX Martin Ratio Rank: 56

AZN

AZN Risk / Return Rank: 84
AZN Sharpe Ratio Rank: 85
AZN Sortino Ratio Rank: 82
AZN Omega Ratio Rank: 80
AZN Calmar Ratio Rank: 87
AZN Martin Ratio Rank: 85

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NVAX vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novavax, Inc. (NVAX) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NVAX	AZN	Difference
Sharpe ratio Return per unit of total volatility	0.44	1.56	-1.11
Sortino ratio Return per unit of downside risk	1.24	2.25	-1.01
Omega ratio Gain probability vs. loss probability	1.14	1.29	-0.15
Calmar ratio Return relative to maximum drawdown	0.70	3.25	-2.55
Martin ratio Return relative to average drawdown	1.48	8.16	-6.68
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NVAX vs. AZN - Sharpe Ratio Comparison

The current NVAX Sharpe Ratio is 0.44, which is lower than the AZN Sharpe Ratio of 1.56. The chart below compares the historical Sharpe Ratios of NVAX and AZN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NVAX	AZN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.44	1.56	-1.11
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.44	0.75	-1.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.20	0.68	-0.88
Sharpe Ratio (All Time) Calculated using the full available price history	-0.07	0.51	-0.58

Correlation

The correlation between NVAX and AZN is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NVAX vs. AZN - Dividend Comparison

NVAX has not paid dividends to shareholders, while AZN's dividend yield for the trailing twelve months is around 2.65%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NVAX Novavax, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
AZN AstraZeneca PLC	2.65%	1.70%	2.27%	2.15%	2.12%	2.35%	2.80%	2.81%	3.69%	3.95%	5.01%	4.06%

Drawdowns

NVAX vs. AZN - Drawdown Comparison

The maximum NVAX drawdown since its inception was -98.82%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for NVAX and AZN.

Drawdown Indicators

	NVAX	AZN	Difference
Max Drawdown Largest peak-to-trough decline	-98.82%	-48.94%	-49.88%
Max Drawdown (1Y) Largest decline over 1 year	-35.94%	-12.24%	-23.70%
Max Drawdown (5Y) Largest decline over 5 years	-98.61%	-27.87%	-70.74%
Max Drawdown (10Y) Largest decline over 10 years	-98.82%	-27.87%	-70.95%
Current Drawdown Current decline from peak	-97.49%	-3.70%	-93.79%
Average Drawdown Average peak-to-trough decline	-70.56%	-11.38%	-59.18%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.94%	4.88%	+12.06%

Volatility

NVAX vs. AZN - Volatility Comparison

Novavax, Inc. (NVAX) has a higher volatility of 15.78% compared to AstraZeneca PLC (AZN) at 7.15%. This indicates that NVAX's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NVAX	AZN	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.78%	7.15%	+8.63%
Volatility (6M) Calculated over the trailing 6-month period	47.46%	19.20%	+28.26%
Volatility (1Y) Calculated over the trailing 1-year period	76.52%	27.33%	+49.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	107.05%	23.85%	+83.20%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	115.25%	24.90%	+90.35%

Financials

NVAX vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Novavax, Inc. and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NVAX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novavax, Inc. reported a gross profit of 123.94M and revenue of 147.14M. Therefore, the gross margin over that period was 84.2%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported a gross profit of 12.39B and revenue of 15.50B. Therefore, the gross margin over that period was 79.9%.

NVAX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novavax, Inc. reported an operating income of 9.63M and revenue of 147.14M, resulting in an operating margin of 6.5%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported an operating income of 2.98B and revenue of 15.50B, resulting in an operating margin of 19.2%.

NVAX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novavax, Inc. reported a net income of 17.53M and revenue of 147.14M, resulting in a net margin of 11.9%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AstraZeneca PLC reported a net income of 2.33B and revenue of 15.50B, resulting in a net margin of 15.0%.